In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Eli Lilly And Co. LLY, a top pick for the firm, is projected to see continued growth in its diabetes and obesity ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently ...
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback